ERBB3 and breast carcinoma: This finding is also in agreement with the study from Kirkegaard et al. [29] demonstrating that the Matrix Metallopeptidase(MMP) inhibitor BB94 blocks the activation of HER3 and ERK and, thereby, tumor cell growth in breast cancer.